French Previously Untreated Patients with Severe Hemophilia A after Exposure to Recombinant Factor VIII : Incidence of Inhibitor and Evaluation of Immune Tolerance

Summary Fifty French previously untreated patients with severe hemophilia A (factor VIII <1%), treated with only one brand of recombinant factor VIII (rFVIII), were evaluated for inhibitor development, assessment of risk factors and outcome of immune tolerance regimen. The median period on study was 32 months (range 9-74) since the first injection of rFVIII. Fourteen patients (28%) developed an inhibitor, four of whom (8%) with a high titer (≥10 BU). All inhibitor patients but one continued to receive rFVIII either for on-demand treatment or for immune tolerance regimen (ITR). Among these patients, inhibitor was transient in 2 (4%), became undetectable in 6 and was still present in 6. The prevalence of inhibitor was 12%. Presence of intron 22 inversion was found to be a risk factor for inhibitor development. Immune tolerance was difficult to achieve in our series despite a follow-up period of 16 to 30 months: immune tolerance was complete in only one out of the 3 patients undergoing low dose ITR and in one out of the 5 patients with high dose ITR.

[1]  B. Kroner,et al.  Analysis of the North American Immune Tolerance Registry (NAITR) 1993–1997: Current Practice Implications , 1999, Vox Sanguinis.

[2]  K. Pasi,et al.  Absence of Inhibitors in Previously Untreated Patients with Severe Haemophilia A after Exposure to a Single Intermediate Purity Factor VIII Product , 1997, Thrombosis and Haemostasis.

[3]  M. Baiget,et al.  Inhibitor Development in Haemophilia A Patients with Inversion of the Intron 22 of the Factor VIII Gene , 1996, Thrombosis and Haemostasis.

[4]  J. Oldenburg,et al.  Immune Tolerance for the Treatment of Factor VIII Inhibitors ‐ Twenty Years' ‘Bonn Protocol’ , 1996, Vox sanguinis.

[5]  J. Oldenburg,et al.  Haemophilia A: Mutation Type Determines Risk of Inhibitor Formation , 1995, Thrombosis and Haemostasis.

[6]  F E Preston,et al.  Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. , 1995, Blood.

[7]  H. M. van den Berg,et al.  Low-dose immune tolerance induction in hemophilia A patients with inhibitors. , 1995, Blood.

[8]  C. Rothschild,et al.  Incidence of Factor VIII Inhibitor Development in Severe Hemophilia A Patients Treated only with One Brand of Highly Purified Plasma-Derived Concentrate , 1995, Thrombosis and Haemostasis.

[9]  G. Auerswald,et al.  Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow‐up , 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  L. Aledort.  Inhibitors in hemophilia patients: Current status and management , 1994, American journal of hematology.

[11]  G. Mariani,et al.  Immune Tolerance in Hemophilia-Principal Results from the International Registry , 1994, Thrombosis and Haemostasis.

[12]  A. Rocino,et al.  Incidence of Factor VIII Inhibitor Development in Hemophilia A Patients Treated with Less Pure Plasma Derived Concentrates , 1994, Thrombosis and Haemostasis.

[13]  D. Cooper,et al.  Screening for inversions in the factor VIII (F8) gene causing severe haemophilia A , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[14]  Stylianos E. Antonarakis,et al.  Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A , 1993, Nature Genetics.

[15]  F. Rosendaal,et al.  Factor VIII inhibitors , 1993, The Lancet.

[16]  M. Hilgartner,et al.  Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII , 1993, The Lancet.

[17]  F. Rosendaal,et al.  A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. , 1993, Blood.

[18]  J. Vermylen,et al.  A Higher than Expected Incidence of Factor VIII Inhibitors in Multitransfused Haemophilia A Patients Treated with an Intermediate Purity Pasteurized Factor VIII Concentrate , 1993, Thrombosis and Haemostasis.

[19]  W. Kreuz,et al.  Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs , 1992, The Lancet.

[20]  H. Kingdon,et al.  Treatment of Hemophilia A with a Highly Purified Factor VIII Concentrate Prepared by Anti-FVIIIc Immunoaffinity Chromatography , 1992, Thrombosis and Haemostasis.

[21]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[22]  K. Brinkhous,et al.  Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure. , 1953, The Journal of laboratory and clinical medicine.

[23]  Shapiro,et al.  A Multicenter Study of Recombinant Factor VI11 (Recombinate): Safety, Efficacy, and Inhibitor Risk in Previously Untreated Patients With Hemophilia A , 2000 .

[24]  D. D. Di Michele,et al.  Immune tolerance: a synopsis of the international experience. , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[25]  J. Arnout,et al.  Factor VIII Inhibitors in Previously Treated Haemophilia A Patients with a Double Virus-inactivated Plasma Derived Factor VIII Concentrate , 1997, Thrombosis and Haemostasis.

[26]  D. Green,et al.  A More Uniform Measurement of Factor VIII Inhibitors , 1975, Thrombosis and Haemostasis.